Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Scleroderma, Localized 1Radiation Injuries 1Prostatic Neoplasms 1Popliteal Cyst 1Polycystic Ovary Syndrome 1Pneumonia 1Neurodermatitis 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lichen Planus 1Leukemia, Hairy Cell 1Leukemia 1Keratoacanthoma 1Keloid 1Hemangioma 1Head and Neck Neoplasms 1Granuloma Annulare 1Dermoid Cyst 1Dendritic Cell Sarcoma, Interdigitating 1Cicatrix, Hypertrophic 1Carcinoma, Non-Small-Cell Lung 1Cancer Pain 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Rituximab 4blinatumomab 3Whole-Body Irradiation 3Cyclophosphamide 3fludarabine phosphate 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Clofarabine 2treosulfan 1thymoglobulin 1sabatolimab 1pembrolizumab 1peginterferon alfa-2a 1obinutuzumab 1midostaurin 1ixazomib 1fludarabine 1eribulin 1daratumumab 1acalabrutinib 1Trastuzumab 1Tacrolimus 1Sodium Chloride 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm, Residual × Adrenal Cortex Hormones × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡